PACIFIC 试验五年生存结局:III 期非小细胞肺癌放化疗后度伐利尤单抗治疗
PACIFIC 是一项 III 期随机对照试验,比较不可切除 III 期非小细胞肺癌同步放化疗后无进展患者接受度伐利尤单抗或安慰剂的疗效。约 5 年更新分析显示,度伐利尤单抗组 5 年总生存率为 42.9%,安慰剂组为 33.4%;5 年无进展生存率分别为 33.1% 和 19.0%,总生存和无进展生存获益持续且稳健。
要点
- 度伐利尤单抗组 5 年总生存率为 42.9%,安慰剂组为 33.4%。
- 度伐利尤单抗组 5 年无进展生存率为 33.1%,安慰剂组为 19.0%。
- 更新分析显示度伐利尤单抗带来稳健且持续的总生存获益和持久的无进展生存获益。
核心结论
- 更新分析显示,放化疗后使用度伐利尤单抗带来稳健且持续的总生存获益和持久的无进展生存获益。
- 估计 42.9% 随机分配至度伐利尤单抗的患者在 5 年时仍存活,33.1% 随机分配至度伐利尤单抗的患者在 5 年时仍存活且无疾病进展,确立了该领域标准治疗的新基准。
研究设计与样本
- III 期 PACIFIC 试验比较度伐利尤单抗与安慰剂用于不可切除 III 期非小细胞肺癌同步放化疗后无疾病进展的患者。
- WHO 体能状态 0 或 1(任何肿瘤程序性死亡配体 1 状态)的患者按 2:1 随机分配至度伐利尤单抗(10 mg/kg 静脉给药;每 2 周一次,持续 12 个月)或安慰剂,按年龄、性别和吸烟史分层。
- 共 713 例患者随机分配,其中 709 例接受了度伐利尤单抗(476 例中 473 例)或安慰剂(237 例中 236 例)治疗。
- 截至 2021 年 1 月 11 日,全患者中位随访 34.2 个月,删失患者中位随访 61.6 个月。
主要发现
- 更新总生存:分层 HR 0.72(95% CI 0.59 至 0.89),中位总生存度伐利尤单抗组 47.5 个月 vs 安慰剂组 29.1 个月。
- 更新无进展生存:分层 HR 0.55(95% CI 0.45 至 0.68),中位无进展生存度伐利尤单抗组 16.9 个月 vs 安慰剂组 5.6 个月。
- 估计 5 年总生存率(95% CI):度伐利尤单抗组 42.9%(38.2 至 47.4)vs 安慰剂组 33.4%(27.3 至 39.6)。
- 估计 5 年无进展生存率(95% CI):度伐利尤单抗组 33.1%(28.0 至 38.2)vs 安慰剂组 19.0%(13.6 至 25.2)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant improvements in the primary end points of overall survival (OS; stratified hazard ratio [HR], 0.68; 95% CI, 0.53 to 0.87; P = .00251) and progression-free survival (PFS [blinded independent central review; RECIST v1.1]; stratified HR, 0.52; 95% CI, 0.42 to 0.65; P < .0001), with manageable safety. We report updated, exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned. METHODS: Patients with WHO performance status 0 or 1 (any tumor programmed cell death-ligand 1 status) were randomly assigned (2:1) to durvalumab (10 mg/kg intravenously; administered once every 2 weeks for 12 months) or placebo, stratified by age, sex, and smoking history. Time-to-event end point analyses were performed using stratified log-rank tests. Medians and landmark survival rates were estimated using the Kaplan-Meier method. RESULTS: Seven hundred and nine of 713 randomly assigned patients received durvalumab (473 of 476) or placebo (236 of 237). As of January 11, 2021 (median follow-up, 34.2 months [all patients]; 61.6 months [censored patients]), updated OS (stratified HR, 0.72; 95% CI, 0.59 to 0.89; median, 47.5 v 29.1 months) and PFS (stratified HR, 0.55; 95% CI, 0.45 to 0.68; median, 16.9 v 5.6 months) remained consistent with the primary analyses. Estimated 5-year rates (95% CI) for durvalumab and placebo were 42.9% (38.2 to 47.4) versus 33.4% (27.3 to 39.6) for OS and 33.1% (28.0 to 38.2) versus 19.0% (13.6 to 25.2) for PFS. CONCLUSION: These updated analyses demonstrate robust and sustained OS and durable PFS benefit with durvalumab after chemoradiotherapy. An estimated 42.9% of patients randomly assigned to durvalumab remain alive at 5 years and 33.1% of patients randomly assigned to durvalumab remain alive and free of disease progression, establishing a new benchmark for standard of care in this setting.
引用
- Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022. PMID: 35108059. doi:10.1200/JCO.21.01308
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。